Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Little Solace for AIDS Victims on the Drug Front




 

Reuters (01/29/90)

London--Pharmaceutical industry analysts expect Burroughs-Wellcome, maker of AZT, to remain the focus of controversy over the drug's high price for the next few years. Although 55 drugs have been developed to treat AIDS in the nine years of the epidemic, AZT apprears to be the only effective antiviral. The next few drugs developed will probably be taken in conjunction with AZT in multi-drug regimens like those used for cancer patients, according to experts. AZT costs patients at least $3,400 per year, and drug-industry analysts say that AIDS sufferers can expect new drugs to be equally expensive because of development costs.



 


Copyright © 1990 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in January 29, 1990. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.